Boston Omaha Corporation (BOC)

CTI BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	22.26	28.29	21.95	25.49	72.51	44.67
Short-Term Investments	49.63	47.35	26.96	15.06	75.35	71.09
Trading Asset Securities	19.25	10.98	47.11	33.52	87.54	37.77
Cash & Short-Term Investments	91.15	86.61	96.02	74.07	235.4	153.52
Cash Growth	30.83%	-9.80%	29.64%	-68.53%	53.33%	-0.24%
Accounts Receivable	10.65	10.27	8.86	5.83	4.47	4.04
Other Receivables	2	2.25	3.47	0.2	0.03	0.29
Receivables	12.65	12.52	12.33	6.03	4.5	24.33
Prepaid Expenses	5.28	5.41	5.57	4.69	2.86	2.2
Restricted Cash	2.2	2.93	3.36	8.15	-	0.28
Other Current Assets	14.89	9.97	14.1	21.03	147.95	148.72
Total Current Assets	126.17	117.45	131.39	113.96	390.71	329.05
Property, Plant & Equipment	225.11	221.34	205.67	180.31	137.71	101.72
Long-Term Investments	138.22	146.52	181.35	144.36	80.98	40.36
Goodwill	182.38	182.38	182.38	179.46	151.34	124.45
Other Intangible Assets	54.35	56.16	62.95	66.62	44.35	44.37
Long-Term Deferred Charges	4.43	4.34	4.36	2.97	1.81	0.69
Other Long-Term Assets	0.18	0.17	0.12	0.12	0.16	0.07
Total Assets	730.84	728.35	768.21	687.8	807.05	640.71
Accounts Payable	19.1	22.25	18.44	10.96	10.27	6.83
Accrued Expenses	-	-	-	-	15	-
Current Portion of Long-Term Debt	1.56	1.2	0.81	1.55	1.49	1.28
Current Portion of Leases	5.3	5.33	5.09	5.2	4.58	4.35
Current Unearned Revenue	15.92	16.03	12.33	9.69	7.12	5.87
Other Current Liabilities	15.01	10.1	14.72	25.58	15.56	15.54
Total Current Liabilities	56.89	54.91	51.39	52.98	54.03	33.87
Long-Term Debt	41.15	38.36	26.52	26.95	28.51	21.78
Long-Term Leases	55.84	54.99	56.44	59.28	56.03	47.58
Long-Term Deferred Tax Liabilities	11.74	11.93	12.11	14.94	17.75	0.06
Other Long-Term Liabilities	5.47	5.43	5.3	3.91	10.14	10.83
Total Liabilities	171.08	165.63	151.75	158.06	166.46	114.11
Common Stock	0.03	0.03	0.03	0.03	0.03	0.03
Additional Paid-In Capital	540.35	539.13	522.51	483.92	483.86	424.2
Retained Earnings	-5.42	-4.75	15.67	22.67	12.44	-42.67
Treasury Stock	-1.68	-1.59	-	-	-	-
Total Common Equity	533.29	532.82	538.21	506.62	496.33	381.57
Minority Interest	26.47	29.9	78.24	23.12	144.27	145.03
Shareholders' Equity	559.76	562.72	616.45	529.74	640.6	526.59
Total Liabilities & Equity	730.84	728.35	768.21	687.8	807.05	640.71
Total Debt	103.85	99.89	88.86	92.98	90.61	74.99
Net Cash (Debt)	-12.7	-13.28	7.16	-18.91	144.79	78.53
Net Cash Growth	-	-	-	-	84.38%	-6.33%
Net Cash Per Share	-0.40	-0.42	0.23	-0.64	4.98	3.06
Filing Date Shares Outstanding	31.45	31.45	31.35	30.82	29.7	27.23
Total Common Shares Outstanding	31.45	31.47	31.31	29.71	29.7	27.23
Working Capital	69.27	62.54	80	60.98	336.68	295.18
Book Value Per Share	16.95	16.93	17.19	17.05	16.71	14.01
Tangible Book Value	296.56	294.28	292.88	260.53	300.64	212.75
Tangible Book Value Per Share	9.43	9.35	9.35	8.77	10.12	7.81
Land	0.58	0.58	0.58	14.32	7.04	0.36
Buildings	67.67	67.16	65.74	63.59	56.09	42.86
Machinery	17.01	16.85	16.08	11.66	8.43	4.67

Updated Mar 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q